( )
Like oral Wegovy, Orforglipron is also a once-daily GLP-1 agonist, but unlike Wegovy, which is protein-based, its a non-peptide medication
Survodutide has received FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis), showing particular promise for liver-related conditions
Both are compounded from licensed 503A pharmacies, both are HSA/FSA eligible, and both work toward the same weight loss goal
Meanwhile, the plaintiffs have filed confidential court documents opposing Novo Nordisks efforts to prevent their medical experts from testifying about the potential link between Rybelsus and gastrointestinal and other side effects
Initial blood glucose-lowering effects typically begin within the first week of treatment, though modest initially